Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02489513 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120
A Phase 1 study, sponsored by Agios Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02489513: Completed Phase 1 study, sponsored by Agios Pharmaceuticals.
NCT02489513 is a Phase 1 study that has completed, run by Agios Pharmaceuticals. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02489513, a Phase 1 study, has completed, sponsored by Agios Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The study is designed to characterize the absorption, metabolism, and excretion of AG-120 using radiolabeled drug in healthy adult male subjects to support its further development and registration.
Primary Outcome
Total \[14C\]-radioactivity in whole blood and plasmafollowing oral administration of a single 500-mg (approximately 200 μCi) radiolabeled dose of AG-120 in male subjects
Interventions
- DRUG [14C]-AG-120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
What the finished NCT02489513 record still lists
NCT02489513 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which [14C]-AG-120 is the first listed.
NCT02489513 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02489513 about?
NCT02489513 is a clinical study titled "Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120". The study is designed to characterize the absorption, metabolism, and excretion of AG-120 using radiolabeled drug in healthy adult male subjects to support its further development and registration.
What is the current status of trial NCT02489513?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-06. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02489513?
The interventions under investigation include: [14C]-AG-120 (DRUG).
Who is sponsoring clinical trial NCT02489513?
This trial is sponsored by Agios Pharmaceuticals, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02489513's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia